Is Human immunoglobulin g registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 7 valid registrations of Human immunoglobulin g, including INTRATECT 50MG-ML SOLUTION FOR INFUSION (50 mg/ml, Solution for infusion, SAR 4482.80); PRIVIGEN 10% SOLUTION FOR INFUSION (10 %, Solution for infusion, SAR 1120.70).

Active substance

Human immunoglobulin g

SFDA 22

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
INTRATECT 50MG-ML SOLUTION FOR INFUSION	50 mg/ml	Solution for infusion · Intravenous use	1 Vial	SAR 4482.80	Biological · Prescription	BIOTEST	Valid
INTRATECT 50MG-ML SOLUTION FOR INFUSION	50 mg/ml	Solution for infusion · Intravenous use	1 Vial	SAR 2241.40	Biological · Prescription	BIOTEST	Valid
INTRATECT 50MG-ML SOLUTION FOR INFUSION	50 mg/ml	Solution for infusion · Intravenous use	1 Vial	SAR 1120.70	Biological · Prescription	BIOTEST	Valid
INTRATECT 50MG-ML SOLUTION FOR INFUSION	50 mg/ml	Solution for infusion · Intravenous use	1 Vial	SAR 448.30	Biological · Prescription	BIOTEST	Valid
PRIVIGEN 10% SOLUTION FOR INFUSION	10 %	Solution for infusion · Intravenous use	1 Bottle	SAR 1120.70	Biological · Prescription	CSL BEHRING	Valid
PRIVIGEN 10% SOLUTION FOR INFUSION	10 %	Solution for infusion · Intravenous use	1 Bottle	SAR 2241.40	Biological · Prescription	CSL BEHRING	Valid
PRIVIGEN 10% SOLUTION FOR INFUSION	10 %	Solution for infusion · Intravenous use	1 Bottle	SAR 4482.80	Biological · Prescription	CSL BEHRING	Valid
ENDOBULIN S\D 5% IV INFUSION	5 %	Solution · Intravenous use	1 Bottle	SAR 2241.40	Biological · Prescription	Takeda Manufacturing AG	Withdrawn by MAH · Not Marketed
ENDOBULIN S\D 5% IV INFUSION	5 %	Solution · Intravenous use	1 Bottle	SAR 4482.80	Biological · Prescription	Takeda Manufacturing AG	Withdrawn by MAH · Not Marketed
ENDOBULIN S\D 5% IV INFUSION	5 %	Solution · Intravenous use	1 Bottle	SAR 224.15	Biological · Prescription	Takeda Manufacturing AG	Withdrawn by MAH · Not Marketed
ENDOBULIN S\D 5% IV INFUSION	5 %	Solution · Intravenous use	1 Bottle	SAR 1120.70	Biological · Prescription	Takeda Manufacturing AG	Withdrawn by MAH · Not Marketed
FLEBOGAMMA 5% SOLU. FOR I.V. INJECTION	5 %	Solution for infusion · Intravenous use	1 Vial	SAR 2942.55	Biological · Prescription	INSTITUTO GRIFOLS	Withdrawn by MAH · Not Marketed
FLEBOGAMMA 5% SOLU. FOR I.V. INJECTION	5 %	Solution for infusion · Intravenous use	1 Vial	SAR 1471.30	Biological · Prescription	INSTITUTO GRIFOLS	Withdrawn by MAH · Not Marketed
FLEBOGAMMA 5% SOLU. FOR I.V. INJECTION	5 %	Solution for infusion · Intravenous use	1 Vial	SAR 735.65	Biological · Prescription	INSTITUTO GRIFOLS	Withdrawn by MAH · Not Marketed
FLEBOGAMMA 5% SOLU. FOR I.V. INJECTION	5 %	Solution for infusion · Intravenous use	1 Vial	SAR 153.80	Biological · Prescription	INSTITUTO GRIFOLS	Withdrawn by MAH · Not Marketed
GAMMA GLOBULIN 16% INJ	16 %	Solution for injection · Intravenous use	1 Ampoule	SAR 7.70	Biological · Prescription	OCTAPHARMA	Withdrawn by MAH · Not Marketed
GAMMAGARD S-D 0.5GM\10ML VIAL	50 mg/ml	Powder and solvent for solution for infusion · Intravenous use	1 Vial	SAR 967.45	Biological · Prescription	BAXTER	Withdrawn by MAH · Not Marketed
GAMMAGARD S-D 0.5GM\10ML VIAL	50 mg/ml	Powder and solvent for solution for infusion · Intravenous use	1 Vial	SAR 549.70	Biological · Prescription	BAXTER	Withdrawn by MAH · Not Marketed
GAMMAGARD S-D 0.5GM\10ML VIAL	50 mg/ml	Powder and solvent for solution for infusion · Intravenous use	1 Vial	SAR 312.30	Biological · Prescription	BAXTER	Withdrawn by MAH · Not Marketed
GAMMAGARD S-D 0.5GM\10ML VIAL		Powder and solvent for solution for infusion · Intravenous use	1 Vial	SAR 78.35	Biological · Prescription	BAXTER	Withdrawn by MAH · Not Marketed
INTRAGLOBIN 2.5G +50ML DILUENT	2.5 g	Solution · Intravenous use	1 Vial	SAR 691.95	Biological · Prescription	BIOTEST	Withdrawn by MAH · Not Marketed
PENTAGLOBIN AMP I.V		Solution for infusion · Intravenous use	1 Ampoule	SAR 448.30	Biological · Prescription	BIOTEST	Invalid · Not Marketed

Indications — CHI Daman Drug Formulary

ACQUIRED HEMOPHILIA; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); GUILLAIN-BARRE SYNDROME; IMMUNE THROMBOCYPTOPENIC PUPURA; MYASTHENIA GRAVIS; MYOSITIS; OPTIC NEURITIS; PEMPHIGUS; POMPE DISEASE (IOPD/LOPD); RENAL TRANSPLANT

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.